Glycemic control in type 2 diabetes: time for an evidence-based about-face?
about
Different intensities of glycaemic control for pregnant women with pre-existing diabetesIntensive glucose control versus conventional glucose control for type 1 diabetes mellitusDifferent intensities of glycaemic control for pregnant women with pre-existing diabetesIntensive glucose control versus conventional glucose control for type 1 diabetes mellitusDifferent intensities of glycaemic control (tight versus very tight) for pregnant women with pre-existing diabetesDifferent intensities of glycaemic control for pregnant women with pre-existing diabetesGuidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure.Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trialDose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure.The pursuit of preventive care for chronic illness: turning healthy people into chronic patients.Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database"Tight control" in geriatrics: the emperor wears a thong.An Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment.Relationship between glycemic control and gastric emptying in poorly controlled type 2 diabetes.Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes.Changing Diagnostic and Treatment Criteria for Chronic Illness: A Critical Consideration of their Impact on Low-Income Hispanic PatientsHealth economic evaluation of type 2 diabetes mellitus: a clinical practice focused review.Optimizing care in diabetes: a quixotic challenge.Reach and Validity of an Objective Medication Adherence Measure Among Safety Net Health Plan Members with Diabetes: A Cross-Sectional Study.Relation between hemoglobin a(1c) and outcomes in heart failure patients with and without diabetes mellitus.Medication burden in the first 5 years following diagnosis of type 2 diabetes: findings from the ADDITION-UK trial cohort.Community healthcare in Israel: quality indicators 2007-2009Quality of life and patient-perceived difficulties in the treatment of type 2 diabetesHyperglycemia effect on coronary disease in patients with metabolic syndrome evaluated by intracoronary ultrasonography.Death during intensive glycemic therapy of diabetes: mechanisms and implications.General and gender characteristics of type 2 diabetes mellitus among the younger and older age groups.A clinical audit on diabetes care in patients with type 2 diabetes in Al-ain, United arab emirates.Control of risk factors for cardiovascular disease among adults with previously diagnosed type 2 diabetes mellitus: a descriptive study from a middle eastern arab population.Public health implications of recommendations to individualize glycemic targets in adults with diabetes.Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies.Getting under the skin of clinical inertia in insulin initiation: the Translating Research Into Action for Diabetes (TRIAD) Insulin Starts ProjectSimultaneous control of diabetes mellitus, hypertension, and hyperlipidemia in 2 health systems.Treated glycosylated hemoglobin levels in individuals with diabetes mellitus vary little by health status: A retrospective cohort study.Intensive Glycemic Control in Type 2 Diabetes Mellitus -- A Balancing Act of Latent Benefit and Avoidable Harm: A Teachable Moment.Gender differences in cardiovascular risk factors in incident diabetes.Diabetes health information technology innovation to improve quality of life for health plan members in urban safety netThe safety profile of exogenous insulin in people with type 2 diabetes: justification for concern.Clinical efficacy of colesevelam in type 2 diabetes mellitus.Optimal management of type 2 diabetes: the evidence.
P2860
Q24185789-A7B04529-CD51-4D90-9831-55F6800B6DB5Q24200376-3ACD7AE5-CDEC-40C2-B5BD-A3027913CA82Q24201483-8454AD2B-2FF4-4B73-A618-76240B6A7484Q24234960-65D07F94-DAAC-4DBC-89B4-D3789667B8D8Q24235120-089C596F-AC8C-4123-AC1F-7C8BDE2CB031Q24235468-A2DEB089-661A-415F-BED5-2EB0D0DA982CQ30426632-5F561555-3AC1-4730-867A-A95F7DC8A23BQ33710663-EB17C9AE-AD8D-4034-8E1C-BD9E7693E7B8Q33751427-6DAC8D08-5C93-41B3-8FA5-158329B866B7Q33815573-98348816-273C-4D70-902B-B044A2E32419Q33818794-FE4BC603-9856-4E2B-B149-F4E27782917FQ33873040-AA27DD7E-2B8E-441E-870F-A052B3D1AD27Q34293277-DC88DB88-499C-481E-9F0D-EDFD03E88129Q34548875-EE43C324-45C2-49DF-9A1B-76C6AF73DE6AQ34979791-B563ED4C-1AC9-4B66-A415-C17C8B6E0FFAQ35043833-11CD49E1-7D44-491E-810A-FA88C53F31C8Q35194766-2894CDB0-6FC1-43E6-8137-FE36E330C8E2Q35219344-8C865E74-6BBF-4C84-924C-1F49ED90271AQ35976546-B8ABE837-FC68-4ACB-9DBE-AAB2A08CC4E2Q36006414-3FF7DE39-B693-4FF9-982B-7676E7E63662Q36007665-1C730B38-37E0-4C64-A332-0FD143F2FFDFQ36120047-7A5EAFDE-0069-4D1C-ADD7-105A2C29D843Q36151700-83A2DDF9-05F8-4019-A8A3-45C51B238F12Q36250624-2FADC1FB-AFA0-47CC-B027-49D0BE5DBC85Q36277039-2422579D-9DC4-4664-B7F8-E231142410A5Q36297059-4FE14FDC-0107-4B16-BE4D-B1E435535C3FQ36321269-49F1DE12-A9F4-4691-9CF2-5BDFDA9652D3Q36365124-1F532D74-F34E-4716-B3EA-AC5C6AB8F05DQ36395447-B43EC9EB-897F-4E90-9D8C-249304B2FE60Q36477793-A47DF927-06D8-4AA2-BDAC-AF791B44F062Q36523427-F7354FA4-FA47-422F-BA95-7E070D0CB77BQ36570779-DC08E69F-291D-4CC8-B370-0779E964848EQ36662100-B6392E40-AB61-4DD5-8E3B-1B9C8B96E8ECQ37205706-C7E9DD31-2013-4851-9B28-1B929B3BD28DQ37310949-3DAF4216-D177-4A0C-B3D6-9302110C87C7Q37599524-EDFC7F82-E2A0-4FB3-91FC-2145E7155376Q37708584-B1D2006D-B732-49C7-8F8D-789B1D9880CDQ37898750-E92E6687-84B7-4930-805A-A48D4D30D322Q37911144-354C9383-7562-4CFF-9964-9ED113D5B387Q37961236-DA543C90-43E5-4872-AC80-857FB5D1B24A
P2860
Glycemic control in type 2 diabetes: time for an evidence-based about-face?
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Glycemic control in type 2 diabetes: time for an evidence-based about-face?
@ast
Glycemic control in type 2 diabetes: time for an evidence-based about-face?
@en
Glycemic control in type 2 diabetes: time for an evidence-based about-face?
@nl
type
label
Glycemic control in type 2 diabetes: time for an evidence-based about-face?
@ast
Glycemic control in type 2 diabetes: time for an evidence-based about-face?
@en
Glycemic control in type 2 diabetes: time for an evidence-based about-face?
@nl
prefLabel
Glycemic control in type 2 diabetes: time for an evidence-based about-face?
@ast
Glycemic control in type 2 diabetes: time for an evidence-based about-face?
@en
Glycemic control in type 2 diabetes: time for an evidence-based about-face?
@nl
P1476
Glycemic control in type 2 diabetes: time for an evidence-based about-face?
@en
P2093
Mercè Fernández-Balsells
P304
P356
10.7326/0003-4819-150-11-200906020-00008
P407
P577
2009-04-20T00:00:00Z